HER2-targeted therapies have dramatically changed the outcomes in patients with HER2-driven breast cancers, with the median overall survival for metastatic HER2-positive breast cancer reaching over 4 years and over one-third of patients surviving at 8 years [3]. The gene discussed is ERBB2; the disease is breast cancer.